Purpose We conducted a systematic review and individual patient data (IPD) meta-analysis to examine the utility of cystatin C for evaluation of glomerular function in children with cancer. Methods Eligible studies evaluated the accuracy of cystatin C for detecting poor renal function in children undergoing chemotherapy. Study quality was assessed using QUADAS-2. Authors of four studies shared IPD. We calculated the correlation between log cystatin C and GFR stratified by study and measure of cystatin C. We dichotomized the reference standard at GFR 80 ml/min/1.73m 2 and stratified cystatin C at 1 mg/l, to calculate sensitivity and specificity in each study and according to age group (0-4, 5-12, and ≥ 13 years). In sensitivity analyses, we investigated different GFR and cystatin C cut points. We used logistic regression to estimate the association of impaired renal function with log cystatin C and quantified diagnostic accuracy using the area under the ROC curve (AUC). Results Six studies, which used different test and reference standard thresholds, suggested that cystatin C has the potential to monitor renal function in children undergoing chemotherapy for malignancy. IPD data (504 samples, 209 children) showed that cystatin C has poor sensitivity (63%) and moderate specificity (89%), although use of a GFR cut point of < 60 ml/min/1.73m 2 (data only available from two of the studies) estimated sensitivity to be 92% and specificity 81.3%. The AUC for the combined data set was 0.890 (95% CI 0.826, 0.951). Diagnostic accuracy appeared to decrease with age. Conclusions Cystatin C has better diagnostic accuracy than creatinine as a test for glomerular dysfunction in young people undergoing treatment for cancer. Diagnostic accuracy is not sufficient for it to replace current reference standards for predicting clinically relevant impairments that may alter dosing of important nephrotoxic agents.
Introduction
Causes of glomerular dysfunction in children with cancer include direct and indirect effects of the malignant process and its treatment, and a range of potentially additive side effects from chemotherapy, radiotherapy, surgery, immunotherapy or supportive treatment. Glomerular impairment is variable in severity and potential reversibility. Renal dysfunction frequently impacts on the management of children with cancer, and in particular may have important implications for the ability to deliver optimal chemotherapy [1, 2] .
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It is important to evaluate glomerular function in children with cancer since glomerular filtration is a major determinant of renal excretion and hence the systemic clearance of some important chemotherapy (e.g., carboplatin) and supportive care drugs (e.g., aciclovir) [2] . Accurate assessment is important since the therapeutic index of many of these drugs is narrow, with even relatively small differences in systemic exposure leading to potential under-treatment and hence poorer anti-tumor efficacy or over-dosage and risk of significant toxicity. However, current approaches to measuring glomerular function in children have important limitations, including their accuracy and practicability [3] . Measurement of serum creatinine and/or urea concentrations is a straightforward and inexpensive test but does not detect milder degrees of glomerular dysfunction, while more accurate measurement of glomerular filtration rate (GFR) is time-consuming, invasive and expensive [4] . A simple, reliable, blood test capable of evaluating glomerular function accurately would be valuable.
Plasma cystatin C is a promising new serum marker for monitoring renal function. Several studies have investigated its utility as a measure of glomerular function, and some have suggested that it should be used in clinical practice. However, we are not aware of any previous systematic review of these studies from the perspective of using cystatin C as a screening test to identify children with adequate renal function, with the ultimate aim of decreasing the number of children in whom formal measurements of GFR are required.
Individual patient data (IPD) pooled analysis of data from randomized trials can facilitate consistent approaches to the control of patient characteristics at baseline and has particular advantages for subgroup analyses [5, 6] . It has recently been promoted for the synthesis of diagnostic accuracy data, but few reviews of diagnostic test accuracy data have used IPD [7] . Potential benefits of diagnostic IPD analysis include the use of information about the receiver operating characteristic (ROC) curve that is not captured in summary (2 × 2) tables of diagnostic accuracy, the potential to examine diagnostic accuracy within patient subgroups, and enhanced statistical precision compared with analyses of individual studies. We examined the utility of cystatin C for evaluation of glomerular function in children with cancer based on IPD combined from four studies and compared results to those obtained using summary data.
Methods

Literature searches
Diagnostic test accuracy (DTA) studies were identified by searching MEDLINE, EMBASE, Biosis, Science Citation Index, and LILACS from inception to June 2009. The MEDLINE search was updated in February 2017. In addition, information on studies in progress, unpublished research or research reported in the grey literature was sought by searching a range of relevant databases including Zetoc, SIGLE, Dissertation Abstracts, the metaRegister of Controlled Trials, NTIS and the GrayLit network. The search strategy was based on combining terms for the index test (cystatin C) and target condition (renal function) and limiting results to studies in children. Full details of the search strategy are available from the authors on request.
Selection of studies
Studies that were eligible for inclusion evaluated the accuracy of cystatin C for the detection of poor renal function/reduced GFR in children undergoing chemotherapy against a reference standard consisting of 24-h creatinine clearance, inulin clearance, or radioisotope glomerular function marker disappearance curve. Two reviewers independently screened the search results. Full text papers were assessed for inclusion by one reviewer and checked by a second. Disagreements were resolved through consensus.
Extraction of summary data and quality assessment
Summary data on participants, index test, reference standard, 2 × 2 tables of diagnostic accuracy, sensitivity, specificity, and measures of correlation were extracted from the published study reports using data extraction forms developed using Microsoft Access. Where available, data stratified according to age were extracted separately for different age groups. Study quality was assessed using the QUADAS-2 tool [8] . This includes domains covering bias due to selection of participants, index test, reference standard and flow and timing. The first three domains are also assessed in terms of applicability to the review question. Data extraction and quality assessment were carried out by one reviewer and checked by a second.
Individual patient data
Authors of the published studies were contacted and invited to take part in the BCystatin C in Childhood Cancer Collaboration^(CCiCCC) in 2010. They were asked to share the individual patient data (IPD) from their study to facilitate analyses that could not be conducted based on summary data alone. Facilities were set up to allow secure transfer of data. Authors were asked to upload a dataset containing the following data, if available: underlying tumor type, chemotherapy type and date of last cycle, other treatment, comorbidity, age, gender, height, weight, BMI, number of samples tested for cystatin C, numerical results for each cystatin C test, dates of each cystatin C test, number of samples tested using the reference standard, numerical results for each reference standard assessment, dates of each reference standard assessment, other tests conducted, results of all other tests, if the patient did not receive both the cystatin C test and reference standard, reasons for this. The data request form is available as a web appendix.
Analysis of summary data
There were insufficient data to allow diagnostic meta-analysis of summary data, so instead a narrative synthesis was presented. Measures of correlation between cystatin C and GFR were summarized. Ranges of sensitivity and specificity were calculated. Estimates of sensitivity and specificity were plotted in ROC space.
Analysis of individual patient data
We standardized definitions and categorizations of variables across studies as far as practicable and agreed a common set of variables to be combined from each study. Data were combined into a single dataset with an additional variable for study number (1 to 4). When considering cystatin C and creatinine as continuous variables, we log transformed the measures because their distributions were right-skewed. We investigated the association between cystatin C and GFR (the reference standard): we calculated the correlation between log cystatin C and GFR, stratified by study and by cystatin C sample number if multiple measures were made in the same individual. For further analyses, we selected the first sample per person. We dichotomized the GFR reference standard at 80 ml/min/1.73m 2 , with values below this indicating impaired renal function. We dichotomized cystatin C at 1 mg/l, with values above this indicating poor renal function. We used 2 × 2 tables of dichotomized GFR and cystatin C to calculate sensitivity and specificity at these thresholds in each study. We used fixed-effect logistic regression to estimate the association of impaired renal function (GFR) with the serum markers of renal function (cystatin C and creatinine). For these regression models, log cystatin C and log creatinine were converted into z scores with mean zero and standard deviation (SD) one in the combined dataset, enabling comparisons of their effects for an equivalent one SD change in each serum marker. We fitted separate models for each study and a combined model across the studies that included an indicator variable for study number. We quantified diagnostic accuracy using the area under the ROC curve (AUC) in models that included (i) log cystatin C, (ii) log creatinine (iii), for the studies for which data on both of these variables were available. To investigate variation in diagnostic accuracy with age we fitted separate models for different age groups (0-4, 5-12, and ≥ 13 years). As sensitivity analyses, we (1) investigated different cystatin C cut points to establish what threshold would provide sensitivity greater than 98%, (2) investigated cut points of < 60 and < 90 ml/min/1.73m 2 for defining impaired renal function for the GFR reference standard, and (3) allowed for repeated samples within patients. We used multilevel mixed-effects logistic regression model in Stata version 14 and used the Bsomersd^command with the cluster option to calculate the AUC allowing for the repeated measures [9] .
Results
The searches identified 2621 studies, of which six diagnostic cohort studies met inclusion criteria [10] [11] [12] [13] [14] [15] . Two of these were available only in abstract form [11, 14] . The six studies included 342 children (range 28 to 99) and more than 545 samples (range 31 to 276; not reported in one study). Mean age ranged from 3.2 to 11.3 years and the proportion of girls ranged from 26 to 64%. The studies included patients with various different cancers. Only one study reported on chemotherapy regimen, which varied between children. Five studies used immunonephelometric methods to measure cystatin C concentration; the remaining study did not report on how cystatin C was measured [11] . Three studies did not use a threshold to dichotomize cystatin C test result [10] [11] [12] : the threshold varied between the remaining three studies. Four studies used radioisotope plasma clearance techniques as the reference standard to measure GFR as an indicator of kidney function [10] [11] [12] 14] . Two studies used a threshold of < 90 ml/ min/1.73m 2 and one a threshold of < 100 ml/min/1.73m 2 as an indicator of impaired kidney function; the other did not dichotomize GFR. One study used 24-h urine collection creatinine clearance as an estimate of GFR, with the threshold for normal GFR varying based on age and gender [15] . The final study used inulin clearance measured using blood sampling at various time points after injection of polyfructosan, with a threshold of < 90 ml/min/1.73m 2 indicating abnormal GFR. A summary of the six published studies is provided in Table 1 .
The results of the QUADAS-2 assessment are summarized in Web Fig. 1 . All studies were judged at low or unclear risk of bias and concerns regarding applicability for all domains. Two studies were judged at low risk of bias for patient spectrum [13, 15] ; four were judged at unclear risk of bias as they did not provide sufficient information on how patients were enrolled into the studies. Three studies were judged at unclear risk of bias for the flow and timing domain as it was unclear whether all enrolled patients contributed to the analysis. The only concern regarding applicability was one study [14] that used a higher reference standard threshold than commonly used to define an abnormal glomerular filtration rate (< 100 mL/min/1.73m 2 ). 
Summary data
Three studies provided measures of correlation between cystatin C and the reference standard (Web Table 1 ). [11, 12, 15] . Two studies suggested a strong negative correlation and one suggested a weaker correlation. Three studies, including one that provided correlation data, [15] reported data on sensitivity and specificity [13] [14] [15] . One of these did not provide sufficient data to construct a 2 × 2 table of test performance as it was unclear how many patients were classed as having normal/abnormal GFR [14] . One study did not provide summary data on either correlation or accuracy [10] .
Estimates of sensitivity and specificity plotted in ROC space from the three studies which provided data on the accuracy of cystatin C are shown in Fig. 1 [13 -15] . One study provided estimates of sensitivity and specificity for two different age groups and so contributes two points to the graph [15] . Sensitivity ranged from 39 to 100%, specificity ranged from 79 to 94%.
IPD data
Four of the six studies agreed to become members of the 5C collaboration and shared their data [10, 12, 13, 15] . The number of participants and age of included children showed some variation from that reported in the summary data reports of these studies (Table 1 ). The total number of participants was 229 (range 22 to 84 per study) and the number of samples was 504 (range 68 to 262 per study). The median age at first measure ranged from 2.8 to 12.1 years. In the IPD, median cystatin C in the individual studies ranged from 0.74 to 0.89 mg/l. The median GFR ranged from 86.3 to 130.0 ml/min/1.73m 2 . The correlations between log cystatin C and GFR for the first sample per person ranged from − 0.454 to − 0.713 (Web Table 1 ). Correlations between log cystatin C and GFR on the repeated samples, where available, were similar.
Estimates of sensitivity and specificity at a cystatin C threshold of 1 mg/l are shown in Table 2 and Fig. 2 , which also shows individual ROC plots for each study. Sensitivity ranged from 53 to 75% and specificity from 86 to 100%. The estimates combining IPD from all four studies were sensitivity 63.2% (95% CI 46.0%, 78.2%) and specificity 88.9% (83.6%, 93.0%).
Estimates of area under the ROC curve (AUC) for cystatin C were 0.915 (95% CI 0.829, 1.00) for the Lankisch study [15] , 0.862 (0.775, 0.950) for the Barnfield study [12] and 0.792 (0.427, 1.00) for the Blufpand study [13] (Table 3) . It was not possible to construct an ROC curve for the Gronroos study [10] as there were no events of GFR < 80 ml/min/ 1.73m 2 for the first measure per person. There was little evidence that the AUC varied between studies (interaction p = 0.77). The AUC for the combined data set, based on the three studies for which individual ROC curves could be constructed, was 0.890 (95% CI 0.826, 0.951) which is not considered sufficiently accurate for clinical use. Diagnostic accuracy of cystatin C appeared to be highest in the younger age group (AUC 0.945, 95% CI 0.895, 0.996) and to decrease with age ( Fig. 3) . For the Barnfield study, diagnostic accuracy was substantially greater for cystatin C (AUC 0.862) than for creatinine (0.681) and was not improved in the model containing both variables (0.861) compared with cystatin C alone ( Table 3 ). For the Blufpand study, diagnostic accuracy was also substantially greater for cystatin C (0.792) than for creatinine (0.696) and was improved in the model containing both variables (0.883) compared with cystatin C alone. In the Lankisch study diagnostic accuracy for cystatin C was 0.915, but data on creatinine were not available.
The odds ratios from all logistic regression models are shown in Web Table 2 . The unadjusted odds ratios per SD increase in log cystatin C for impaired renal function (GFR) were 9.0 (95% CI 3.1, 26.0; p < 0.001) in the Barnfield study, 4.6 (1.1, 19.3; p = 0.039) in the Blufpand study and 7.5 (3.0, 18.9; p < 0.001) in the Lankisch study. The unadjusted odds ratios per SD increase in log creatinine were lower: 2.2 (1.3, 3.8; p = 0.006) and 0.4 (0.1, 1.7; p = 0.219) in the Barnfield and Blufpand data, respectively. Odds ratios were not substantially changed in models that contained both cystatin C and creatinine. Combined across studies, the odds ratios per SD increase in log cystatin C were 7.4 (4.0, 13.8; p < 0.001) based on the first measure and 9.3 (5.8, 14.9; p < 0.001) based on all measures. The odds ratio per SD increase in log cystatin C was 15.0 (3.1, 71.9) in younger children and 6.1 (2.2, 16.7) in older children (p for interaction = 0.727).
Results from sensitivity analyses showed that estimated sensitivity for a cystatin C threshold of > 0.7 mg/l was 100%, but the corresponding specificity was only 31.6% and more than 70% of patients would be classified as having 'elevated' cystatin C at this threshold. Changing the definition of impaired renal function to < 60 ml/min/1.73m 2 for the GFR reference standard gave estimates of sensitivity of 92.3% (95% CI 64%, 99.8%) and specificity of 81.3% (95% CI 74.2%, 87.2%) from two studies [12, 15] which had values of GFR < 60 ml/min/1.73m 2 for the first measure per person. A GFR cut point of < 90 ml/min/1.73m 2 , give estimates of sensitivity of 58.2% (95% CI 44.1%, 71.3%) and specificity of 91.4% (95% CI 85.7%, 95.3%) from three studies [1, 12, 15] .
The AUC from the model for cystatin C using all data and allowing for repeated measures per person was 0.902 (95% CI 0.861, 0.942); the odds ratio per SD increase in log cystatin C in this model was 9.3 (5.8, 14.9; p < 0.001; Web Table 2 ).
Discussion
Summary of findings
We conducted a systematic review and meta-analysis of published summary data and individual patient data from diagnostic test accuracy studies of cystatin C for diagnosis of impaired renal function in children with cancer. The six available published reports suggested that cystatin C has the potential to monitor renal function in children undergoing chemotherapy for malignancy, but they used different test and reference standard thresholds, and the summary data were impossible to synthesize quantitatively. The IPD analyses provided important additional information and led to clearer conclusions than those possible with published summary data. They showed that at a threshold of > 1 mg/l cystatin C has limited sensitivity (63%) and moderate specificity (89%) for diagnosis of impaired renal function using a cut-off of GFR < 80 ml/min/ 1.73m 2 . Using a threshold which achieved sensitivity 98% (> 0.7 mg/l), 70% of the tested population would have an 'elevated' cystatin C and require further testing with a reference standard test. The sensitivity analysis using different definitions of impaired renal function showed that a GFR cut point of < 60 ml/min/1.73m 2 improved sensitivity, but this was based on the only two studies that included values of GFR < 60 ml/min/1.73m 2 . Diagnostic accuracy for cystatin C was consistent across studies. For the two studies for which data were available, diagnostic accuracy of cystatin C was clearly greater than that of creatinine. However, diagnostic accuracy may not be sufficient to justify the use of cystatin C as a screening test for glomerular dysfunction, because of the practical implications of incorrect classification of renal function, or the large proportion of children in whom a second, definitive test would be required after cystatin C testing. Notes: the GFR reference standard was dichotomized at GFR 80 ml/min/1.73m 2 . Cystatin C and creatinine were log transformed. The Gronroos study was excluded because there were no events of GFR < 80 ml/min/1.73m 2 for the first measure per person. Creatinine data were not available for analysis in our IPD dataset for the Lankisch study as we believe it may have also been used to calculate GFR Fig. 2 ROC plots for cystatin C for predicting GFR for the IPD datasets, stratified by study with additional plot showing summary estimates of sensitivity and specificity Fig. 3 ROC plots for cystatin C for predicting GFR for the combined IPD dataset stratified according to age group These include under-dosing patients with a reduction in anticancer efficacy in whom the test incorrectly reports renal impairment, and excessive dosing with high risks of severe chemotherapy toxicities in those who are incorrectly reported as having sufficient renal function.
Strengths and limitations
The comprehensive and efficient use of IPD data, collected by a collaborative effort from the 5C group, has allowed us to clearly describe the limits of uncertainty with cystatin C in childhood cancer and conclude that this test is not suitable for routine use. Limitations of our review include the small number of studies available on this topic and that we were only able to obtain IPD data for four of the six identified studies, all of which had very small sample sizes (range 22 to 84 children). It is unclear why the other groups declined to participate. The summary data available were insufficient to perform standard meta-analysis and so we were unable to compare the results from summary data meta-analysis with IPD meta-analysis. At the time of this collaboration being commenced, the creatinine-cystatin C-based CKiD equation (2012) had not been developed, and so the IPD to assess the validity of this paediatric chronic kidney disease estimator were not sought and cannot be assessed. The children being treated received a variety of chemotherapy regimens, including platinum, alkylating agents and corticosteroids, which may have variably affected the performance of cystatin C. The reference standard techniques to determine Btrue^GFR varied between studies, and some of the studies were conducted before an agreement on the analysis of creatinine had been confirmed [16] . It is unclear what analytic variation has been introduced by these elements, and the importance of such variation. This issue of how analytic variation affects our estimates of clinical test interpretation remains an area of active academic exploration [17] . There were some discrepancies between what had been reported in the publications of the studies and the IPD that were provided to us, for example the number of samples. While studies investigating other markers are being developed, consideration should be given by clinical researchers to regularly enter into collaboration with other academics, guided by partners skilled in meta-analysis, to produce results which are more precise and globally applicable than any one study group would achieve.
Comparison with existing literature
Cystatin C has been promoted as a marker of renal function in a variety of conditions, for example post-renal transplant in adults [18] or children [19] , or in adults with malignancy [20] . Other uses for the marker include the prediction of mortality in adult populations with and without renal impairment [21] , with high-risk conditions such as type 2 diabetes [22] or in critical care units [23] . The clinical utility of cystatin C differs according to the indication [22, 23] . The accuracy of cystatin C-based measurements is consistently better than those based on creatinine alone, and may be reasonable to use at a population-based level [24] . However, these measurements have previously been shown not to be useful as a basis for chemotherapy dosing decisions [25] .
These findings place cystatin C in a similar situation to existing tests for renal impairment, which all have important challenges in their regular clinical use. Routinely measured creatinine has insufficient accuracy as a serum marker for renal function, especially in children [26] . Serum concentrations of creatinine and particularly urea are insensitive, with abnormal values not seen until the glomerular filtration rate (GFR) has fallen by 30-50% [10] . GFR can be estimated from formulae including serum creatinine concentration and patient height but their utility in determining GFR in children with cancer has been shown to be low [27, 28] . The creatinine clearance method requires accurately timed urine collections which are difficult to achieve reliably in children, overestimates GFR due to tubular secretion of creatinine and has been shown to be poorly reproducible [4] . The inulin clearance method is technically difficult since inulin is not routinely measured in clinical laboratories, and requires an intravenous inulin infusion and again, a timed urine collection.
Where an accurate measurement of glomerular function is required to dose chemotherapy, it remains important to use plasma radioisotope clearance (e.g., 51 Cr-EDTA clearance), despite the logistical limitations and exposure to low dose radiation [4] . However, non-radioisotopic but equally labor-intensive methods such as the use of iohexol clearance GFR measurements are now available in some children's hospitals.
Implications for future research
Further research could examine whether particular clinical situations alter the clinical utility of cystatin C testing. Our data were insufficient to determine if the diagnostic accuracy of cystatin C varied between risk groups, for example those exposed to multiple courses of nephrotoxic agents, who had documented episodes of acute kidney injury during their therapy, or with high body mass index. Such research would benefit from multi-institutional collaboration, as clinically important glomerular dysfunction is uncommon in children with cancer.
Conclusions
Cystatin C is more useful than creatinine as a screening test for glomerular dysfunction in children and young people undergoing treatment for cancer. However, diagnostic accuracy is not sufficient for it to replace current reference standards for predicting clinically relevant impairments that may alter the dosing of important nephrotoxic agents. This conclusion could only be firmly reached after combination of individual patient data from multiple studies. A limited reading of selected publications could lead clinicians into using this test as an easy and effective alternative to assessments using the reference standard, and inadvertently producing incorrect decisions leading to avoidable renal impairment or under-dosing of anticancer agents. Advancing clinical care requires a clear understanding of the value of innovations: describing the limitations of new interventions and technologies is as important as extolling their benefits, and preventing the uptake of unhelpful approaches is a key to effective care as rapidly rolling out beneficial programs of care. Collaborative effort by multinational groups to share and combine data facilitate the evaluations required to make judgments about the role of new tests and interventions in clinical care.
